

KING PHARMACEUTICALS INC

Form 8-K

May 21, 2003

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2003

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Tennessee**  
(State or other jurisdiction  
of incorporation)

**0 24425**  
(Commission  
File Number)

**54-1684963**  
(IRS Employer  
Identification Number)

**501 Fifth Street, Bristol, Tennessee**  
(Address of principal executive offices)

**37620**  
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable  
(Former name or former address, if changed since last report)

---

---

**TABLE OF CONTENTS**

SIGNATURE

Exhibit Index

Ex-99.1 Press Release

---

**Table of Contents**

**Item 5. Other Events**

On May 20, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, announced that it has reached an agreement with Elan Corporation, plc that restructures the terms of the Asset Purchase Agreement dated January 30, 2003. Pursuant to the revised terms of the agreement, the previously announced planned acquisition of Elan's primary care business in the United States and Puerto Rico is expected to close by the end of June 2003, subject to the satisfaction of certain contingencies, including approval by the holders of a majority of the outstanding common stock of Elan and other customary conditions. King and Elan have also agreed to suspend litigation between King and Elan relating to the original agreement until the closing of the transaction, at which time the litigation will be dismissed. On May 20, 2003, King issued a press release regarding the proposed transaction.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

**Exhibits:**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated May 20, 2003.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 21, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi  
James R. Lattanzi  
Chief Financial Officer

---

**Table of Contents**

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated May 20, 2003.